Tomas Duraj "Cancer as a Metabolic Disease" at Keto Symposium NYC 2022 Tomas Duraj MD PhD is a post-doctoral cancer researcher in the biology department at Boston College working with Thomas Seyfried PhD. In this lecture at Keto Symposium NYC, held at Lincoln Center September 2022, he explains cancer as a metabolic disease.
Keto Symposium was hosted by Kristina Hess, a licensed-dietitian specialized in ketogenic therapy and anti-inflammatory programs. To book a consultation visit www.theketonutritionist.com OR www.thriveresultscoaching.com
So I want to introduce our next speaker.
I'm so excited for this talk.
So if you were here yesterday, you
heard me share that in 2017, well, I just
finished my boards and my hours for licensure.
And I was super tired, fatigued, and was really overweight.
And I was doing triathlons, and I couldn't lose the weight.
And I thought, OK, now I'm done.
This should be easy.
I should come right off.
But it wasn't, and I was eating a lot of carbohydrates.
No.
So I went to this nutrition conference,
saw Dr. Thomas Seyfried, expanded my mind.
Conferences are so great for that.
And I'm so pleased to introduce Dr. Thomas Durai today,
because he is a colleague of Dr. Thomas Seyfried.
And Dr. Thomas Seyfried set me on my path
to a ketogenic lifestyle.
And it's my hope that you will also
hear some nugget of information at some point
in this weekend that really blows your mind too,
that keeps you on the path or sets you on your path
if you haven't even gotten started or if you fell off.
So Dr. Durai is a medical doctor of Czech-Austrian origin.
So he is not only an MD, but he's also a PhD.
So he might not have found any of my other amazing,
intelligent, super smart speakers,
but he may get smartest guy in the room award.
His scientific research has focused mainly
on studying the potential of bioenergetic modulation
in cancer metabolism with a special emphasis
on glioblastoma, the most aggressive and lethal
primary brain tumor.
So in his clinical practice, he specializes
in health optimization through nutritional and lifestyle
interventions.
And in his research career, he has
authored original peer-reviewed scientific publications.
And he's lectured on cancer internationally.
And his goal is to advance our understanding
of metabolic therapy, making it a part
of the standard oncology toolkit so that all patients can
benefit.
Please welcome Dr. Thomas Durai.
All right, so it's a great, great pleasure
to be here today to talk to you about cancer
as a mitochondrial metabolic disease.
And in this presentation, I want to give you
a little overview of mitochondria,
what is the mitochondria function and origin.
He talked a little bit about genome part of this.
And we will focus more on the mitochondria.
Then discuss quickly the theories of carcinogenesis,
so what might be the origin of cancer,
and then how to approach prevention and treatment
from the mitochondrial metabolic theory perspective,
including but not limited to the ketogenic diet.
And I know that cancer is not always
on everybody's mind.
It's certainly on my mind all the time.
But I think people are more interested in prevention.
We will discuss that.
But I think it's important for patients
to have access to the best kind of information
and to understand that ketogenic metabolic therapy
can be a powerful tool to manage cancer.
So we need to start at the mitochondria.
At the most basic level of definition,
what are mitochondria?
Mitochondria are intracellular organelles in the cytoplasm.
These are like little, small, isolated subcompartments
that are destined for energy production.
They have many other important functions,
such as control of the cell cycle,
so the division of the cells, apoptosis,
cell signaling, even indirectly immune function.
But we focus in our research mostly
on the bioenergetics of the mitochondria,
and that is how our mitochondria make energy, ATP,
how they make the energy that we need to live.
So just to give you a few concepts
that are necessary to understand my talk,
how is energy generated in our cells?
So we have three distinct processes, distinct categories,
that at the biophysical, biochemical level,
make energy for our cells.
We have OXPHOS, or oxidative phosphorylation.
Oxidative phosphorylation is performed by the mitochondria
from different fuels, through oxidation of different fuels
in T cell cycle, fueling the proton gradient
of the elymph node transport chain,
and making most of the energy
that our non-tumoral oxidative cells use.
And this requires oxygen.
There is no mitochondrial metabolism for ATP synthesis
without oxygen.
And then we have substrate-level phosphorylation, or SLP,
which you also might hear about,
referred about to as fermentation.
And SLP usually provides only a small fraction
of the energy that our cells use.
This is a direct enzymatic process,
so this is like an enzymatic step,
where we have a donor molecule that has a phosphate group,
transfers it to ATP to make ATP to make energy.
And SLP, you usually don't see it in oxidative cells,
and provides, doesn't require oxygen.
So SLP is just an enzymatic step,
where you get a little bit of ATP,
not as efficient as oxidative phosphorylation,
and you can see it upregulated, for example, in hypoxia.
When we exercise the muscle,
and there is not enough oxygen going in,
you see SLP of glucose making lactate,
and that is a process for ATP generation.
We also have photosynthesis, but we are not planned,
so we can skip that, save a little time.
So our animal cells, I want you to remember
that animals with eukaryotic cells
get their energy from OXPHOS and SLP.
So these two concepts are very important
to understand what might happen
if the mitochondria is actually damaged.
And what else is worth knowing about the mitochondria?
I would say two very important things
that we need to keep in mind.
First, even though we usually represent mitochondria
as just one giant mitochondria sitting in a cell,
making all the ATP, and I, myself, am guilty of this.
This is my own paper, scientific paper,
and there is just one mitochondria just making the ATP.
The reality is that we don't have one mitochondria,
but we have the chondrium.
The chondrium is the sum of all the mitochondria
in any given cell, and we usually have,
in our mature tissues, such as the liver
or the brain or the kidney,
we have 100 up to 1,000 mitochondria in a network.
And mitochondria are not a static network of organelles.
They are a highly dynamic network of organelles
that undergoes constant processes of fusion,
of fission, of transport.
Here we can see, this is a 10-minute time lapse
with a scanning confocal microscope,
and we can see mitochondria zipping around
the microtubules in a cell,
so indeed they are very active.
And I know this image might look a little unnerving
because it looks like an infection,
like little bacteria that might be living inside our cells.
And that brings me nicely to the origin of the mitochondria.
So where do the mitochondria come from?
So the proposed origin of the mitochondria
has been proposed in the endosymbiotic theory
of mitochondrial origin that poses that
around two billion years ago,
when the amount of oxygen in the Earth's atmosphere
started to increase,
and oxidative alpha-proteobacteria
that performed oxphos, oxidative phosphorylation,
so this would be a precursor for the current mitochondria,
fused with a hypoxic prokaryotic precursor
that performed SLP.
So remember, there was no oxygen
prior to this moment in evolution,
so the only way to make energy was in hypoxic conditions,
but was using SLP.
And these two formed the eukaryotic cells
capable of generating ATP from different fuels
in the presence of oxygen that we see today.
So remember that the hypoxic prokaryotic precursor of SLP,
basically the genetic instruction,
this brings us back to the genetics,
the genetic instruction of prokaryotes, of bacteria,
and we can still see today,
they proliferate, they are highly proliferative,
they proliferate as long as there is nutrients in the media,
bacteria, prokaryotic cells that do SLP will proliferate.
So when we understand a little bit
about mitochondrial function,
we can talk about the theories of carcinogenesis.
So what is the origin of cancer?
The most, let's say, popular idea,
at least amongst researchers,
is that cancer is a genetic disease.
This is the somatic mutation theory
that has a background of more than 100 years.
And in this theory, cancer is caused by mutations
in oncogenes and tumor suppressor genes.
These can either be inherited, this is quite rare,
these are the genetic predisposition syndromes,
such as the BRCA1, BRCA2,
Li-Fraumeni-Lenz syndrome, neurofibromatosis,
there are many genes that can,
polymorphic genes that can make you
more susceptible to cancer,
and, or they can be spontaneous, random, bad luck events,
which would apply to most cancers.
And this idea was developed in the mid-20th century
with the discovery of the structure of the DNA,
and then further developed in the 90s
with the Human Genome Project,
and that had a very attractive idea at first,
which was, let's sequence the whole genome,
if cancer is a genetic disease,
we sequence the genome,
and we will be able to develop targeted therapies
against cancer and many other diseases.
The problem with this is that, at least for prevention,
if you don't want cancer, you need to avoid mutations,
so of course, you wouldn't expose yourself
to radiation, ionizing radiation, or carcinogens,
but if you don't want mutations,
what you really need to do is to avoid aging,
which is not a very useful recommendation
from a medical perspective.
So, there are more problems with the SMP,
with the somatic mutation theory.
With the Cancer Genome Atlas,
so after the Human Genome Project,
there was another bigger project,
that's the Cancer Genome Atlas,
which aimed to sequence
more than 30,000 tumor samples,
and indeed, it detected 50 up to 100 different mutations
in cancer, in different types of cancer,
so the naive paradigm was invalidated,
that just one mutation would cause one cancer,
that doesn't seem to happen,
and we also get that different patients,
so patient A and patient B
can have exactly the same type of tumor,
the same lifestyle, the same background, the same grade,
and they can have different tumor mutations.
We also have the Nuclear Cytoplasmic Transfer Experiments,
which would suggest that mutations
are not the origin of cancer,
we have sometimes no detectable mutations in tumor tissues,
or we have also mutations in oncogenes,
in actual oncogenes and tumor suppressor genes
in normal tissues, and this has been published
in the top scientific journals in Nature,
and I think these inconsistencies
are starting to be, well, maybe not difficult to ignore,
because they are being ignored,
but you can make the theory more and more convoluted
to try to explain these things
with different ways, epigenetics, microenvironment,
you can have infinite complexity with ad hoc solutions,
but the bottom line, the fact is that this approach
is simply not working,
so of the therapies that have been approved
in the last, let's say, 40 years,
but actually in the whole lifespan of this theory,
the improvements in overall survival are quite slim,
so this is not working, so we need an alternative way
to make therapies actually work.
So how can we make sense of this?
This is a slide from Dr. Seyfried's recent publication,
I think aptly titled,
Can the Mitochondrial Metabolic Theory Explain Better
the Origin and Management of Cancer
than Can the Somatic Mutation Theory?
And for us, the answer is yes,
but let's see if I can explain why I tried to convince you
that this might be the case.
So the first thing that we need to understand
is whenever we talk about defective respiration,
damaged mitochondria, what are we talking about?
So defective respiration,
or defective oxidative respiration,
is chronic damage, sublethal damage,
to the mitochondrial structure, the composition,
the morphology, the function, the number of mitochondria,
the remodeling processes, and of course,
especially the bionergetic functions of the mitochondria.
So we are not talking just about mitochondrial DNA mutations
which are more associated
with inherited mitochondrial diseases,
and so if the mitochondria is too damaged,
this is often incompatible with life.
So just sublethal damage to the mitochondria,
slowly accumulating over time,
also explains the oncogenic paradox,
which has no answer from the somatic mutation theory,
which is how is it possible that different insults
that have nothing to do with really DNA damage
that do not cause DNA damage,
such as inflammation or hypoxia,
can actually also cause cancer?
And what happens when the mitochondria
become slowly damaged?
First, we have the production of reactive oxygen species.
This is a normal byproduct of mitochondrial metabolism,
but an increased oxidative stress
will indeed induce mutations in the genome.
So we are not saying there are no mutations in the genome,
there are many mutations in the genome,
but mutations, somatic mutations,
are a downstream epiphenomena,
are a consequence of the mitochondrial damage.
They are not the cause of cancer itself.
And when the mitochondria starts to be damaged,
so the chondrium, so remember,
you have a mix of mitochondria,
some are still working, some are damaged,
this produces a shift from oxidative phosphorylation,
so the normal function of the mitochondria goes down,
and we see a compensatory increase in SLP,
or substrate-level phosphorylation.
And SLP requires two main fuels,
so cancer cells require two main fuels to grow.
Glucose, so the SLP of glucose is called the Warburg effect,
which I'm sure you are familiar with,
and the SLP of glutamine, sometimes forgotten,
is called the Q effect.
And these two can make energy for the cancer cells,
they can provide energy and even biosynthesis products,
regardless of the presence of oxygen.
So you can be doing SLP, Warburg effect, the Q effect,
even if there is no oxygen,
and that is why cancer cells can actually grow,
even in hypoxia.
And if you take a look back at evolution,
what kind of organism performed SLP of glucose and glutamine,
this was indeed the prokaryote that existed
prior to the fusion with the mitochondria.
And that explains why, when the mitochondria is damaged,
what we see is a regression, let's say,
to an ancient phenotype, genetic phenotype,
and metabolic phenotype, for unbridled proliferation.
As all prokaryotes, the only genetic instruction
for the SLP organisms is unbridled proliferation.
And this also explains all the different hallmarks of cancer
and we conclude that the genome is metabolically determined.
The genome is still important, it's like having the recipe,
but if you don't have the ingredients,
the actual metabolites and the energy,
then the genome by itself doesn't mean much.
So with this perspective in mind,
let's talk a little bit about prevention and treatment.
Unfortunately, I don't have that much time
to get into prevention, but I think most of the other talks
in this conference are going to focus
how to keep your mitochondria healthy.
And so I would say that I want you to think about prevention
from this perspective, from the mitochondrial perspective,
as a milder, more light version of the things
that we are going to do for treatment.
But I think cancer patients are seeking information
and they would benefit more from having information
about how to actually treat cancer once it's developed.
But of course prevention is key,
you need an anti-inflammatory diet, exercise,
fasting, hormetic stressors,
and maybe some supplementation when necessary.
But I want to talk about metabolic therapy in cancer.
And I usually structure this in three levels of intervention
and this is my personal approach
and there might be different ways to go about this.
And I should preface this by saying
that this is an ongoing, active area of research.
And so everything I'm going to say is more
from what I would do with the information
that I have in my head if I was facing a cancer diagnosis.
But each patient is different
and it needs to be personalized.
So the first level, and these first two
are done at the individual patient level,
so you don't really need a doctor to do this.
But the first level, for this you need a doctor,
is to learn as much as possible about cancer,
about the cancer that you might have.
And I don't say this lightly,
and this is something that you won't see published anywhere,
nobody's talking about it,
but I think looking at what I have seen,
this is really not being done correctly
in standard clinical practice.
So the patient or the family members,
they need to have absolute knowledge,
and I mean this, really, absolute knowledge
about what to expect from standard of care.
That means that the patient or the family members
and the oncology team, they need to sit down
and actually read the studies.
This requires a lot of time.
Read the studies that would justify whatever approach
from the standard treatment protocols might be offered,
and to see if it's justified, if it makes sense.
So the chemoradiotherapy protocols,
targeted therapies, immunotherapies,
these are all nice-sounding things,
but these are the gold standard
because they are based on big clinical trials
with hundreds of patients,
and the patients really need to understand,
because the data is there,
they should understand what is the expected efficacy,
what is the toxicity, what are the adverse effects.
And of course, we need to use metabolic imaging,
anatomical imaging, tumor biomarkers,
have a good follow-up plan
to evaluate the response to therapy
if we are doing standard of care.
And then we would move to strict lifestyle interventions.
And I use the word, the moniker, strict,
because the ketogenic diet for cancer
has some characteristics that are,
it's not the same ketogenic diet that you might do
just for weight loss or diabetes.
Fasting, exercise, supplementation,
and I think at the second level,
this can be done by every patient,
there are synergistic opportunities
with standard of care if you choose to do it
in all patients.
I have yet to see a cancer that wouldn't benefit
from doing this second level.
And then, in the third level, we have pharmacology,
we have repurposed drugs and novel agents
that are still in clinical trials
to target mainly metabolism, but other processes as well,
or complementary systemic or local therapies
such as hyperbaric oxygen,
and we will get into detail on this.
So, the ketogenic metabolic therapy.
This is, I call this a special form of the ketogenic diet
because it usually requires caloric restriction,
which you also might do if you want to lose weight,
and fasting, and this is something that's the baseline.
We want to get this right.
And if the weight of the patient doesn't allow it,
which is quite common, then it needs to be cyclical.
There are periods of weight loss
and there are periods of weight recovery.
For me, personally, this might be a little
controversial opinion, for me,
the diet composition itself is inconsequential
in the sense that what we are trying to achieve
is specific measurable parameters.
The ketogenic diet is the only way
to achieve those parameters,
but the diet composition itself
can be tailored to each patient.
And we want to have basically undetectable levels
of insulin, glucose levels as physiologically low
as possible, the BHB levels usually mirror inversely
the glucose levels, they're usually intermediate or high,
and they might have their own benefits on their own.
There's a lot of research looking just at the effects
of ketone bodies in isolation.
Inflammation, of course, is as low as possible.
We should be seeing reduced tumor growth
if we are doing this correctly.
Now, how to measure this?
The GKI, or the Glucose Ketone Index,
is quite an easy way to understand
or to estimate the expected therapeutic benefit
from the ketogenic metabolic therapy.
And these days, it's quite easy to measure,
I have to say, I'm grateful for companies like Keto-Mojo,
because they have made the life of clinicians
much easier to actually get the data.
But what is the optimal number?
Now, the GKI, if you take a look,
is simply the level of glucose in millimolar
divided by the level of ketones in millimolar,
just a division, that give you an index.
And we usually aim at a GKI of under two,
and ideally of as close to one as possible,
or even under one.
Now, a GKI of one, if you visualize it,
is basically the same number of glucose than of ketones.
So you might have four millimolar of glucose
and four millimolar of ketones,
that would give you a GKI of one.
And then, you can either go higher in ketones
or lower in glucose.
And I would say, my intuition,
and looking at the available scientific literature,
is that the glucose levels themselves are,
on itself, an important factor for therapeutic efficacy.
So how low do you need to go
will depend on how aggressive your cancer might be.
I also have to mention, for ketones,
ketones are a non-fermentable metabolic fuel.
That means that they can only be used by our mitochondria,
by oxidative phosphorylation.
And we already established
that cancer mitochondria is damaged.
And so, ketones are really the fuel for our normal cells
to compensate for the lack of glucose
that we are trying to put down as much as possible.
And for, I would say,
this might be still a little controversial
in the scientific literature
and the scientific world, the research,
I have yet to see a cancer cell
that would be able to use ketones for ATP,
for energy, to proliferate,
in the absence of glucose and glutamine.
So this is a challenge for the scientific community.
If anyone knows of any cancer cell
that might use ketones to proliferate
in the absence of glucose and glutamine,
I would be very happy to find that kind of cell
because we have not seen it yet.
And in general, for the GKI,
caloric restriction, ketogenic diet, and fasting,
that's what allows you to sustain a good GKI
for longer, extended periods of time.
Now, what about supplementation?
So we are still in the second level,
and there is an endless list of supplements.
This is not really, we don't have time
to get into detail for each of these.
It's just for cancer patients.
I think this is gonna be recorded.
So cancer patients can pause this
and go into the scientific literature
and find information on each of these compounds
which have shown benefit either in preclinical studies
or small pilot clinical studies for cancer treatment.
And the idea is to use nutrition and supplementation
to target cancer cells selectively
and to optimize the mitochondrial health
in our normal cells, and also to limit
standard-of-care toxicity, if we decide to do it,
and to improve the efficacy of standard-of-care.
What about glutamine?
So we have talked about SLP, substrate-level phosphorylation,
and we said that there are two fuels for cancer to grow.
There is glucose.
We can target glucose quite easily
with ketogenic metabolic therapy, with the diet.
But what about glutamine?
Glutamine is a non-essential amino acid.
That means that, unfortunately, even that sounds great,
but that means that our bodies can make it on their own
from different precursors.
So glutamine cannot be eliminated from the diet.
Even if you are fasting, you will still find glutamine
in your plasma circulating.
So the only way to target glutamine is either by supplements.
Once again, there is a list of them.
Problem with supplements, they usually have low potency,
so you need to combine a few supplements together
to actually inhibit glutamine in a meaningful way.
Or these can be pharmacological agents.
Some of these are FDA-approved.
Others are still in clinical research.
The problem with these is also
they are usually tested in monotherapy.
So, for example, you are doing standard-of-care
and just one glutamine inhibitor,
and we are not expecting to see great results
because you always need to target glucose
and glutamine at the same time.
So that is something that I think
all cancer patients need to keep in mind,
that always glucose and glutamine
needs to be targeted at the same time.
And in the third level,
we have the pharmacological and systemic therapies.
These are guided by the results of the first two.
So we are either doing standard-of-care,
or we know that standard-of-care will not work
because from the first level,
remember, we know everything there is to know
about what to expect from the traditional treatments.
And we are doing level two,
and we are looking at the tumor.
Is it responding?
Are the tumor biomarkers going in the right direction?
Is the size decreasing?
Or we might consider this to prevent a tumor
that has high rates of recurrence.
Once again, there are many ways to target metabolism.
We usually focus on repurposed drugs.
So these are FDA-approved off-label indications,
prescriptions that you might use also to target cancer.
We, of course, want to target cancer metabolism first,
so SLP of glucose and glutamine.
But there are many other processes that,
after this is done, we can also target,
such as inflammation, autophagy, angiogenesis.
We can try to potentiate the immune system,
modulate the redox balance, et cetera, et cetera.
And there are many different protocols
that have been proposed to do this.
I want to remember, once more,
that always you need to use a multilayered approach.
So you need to target glucose and glutamine
at the same time, and you might throw in there
some other pathway regulators
to try to help with the cancer treatment.
And then, in the third level,
we also have the systemic therapies.
The one that I am most familiar with is HIBOT,
hyperbaric oxygen therapy.
And this, together with ozone therapy and IV vitamin C,
they have similar mechanisms of action
in the sense that you are trying to increase
ROS production, so reactive oxygen species,
in the tumor cells, where the mitochondria is damaged,
to try to selectively kill tumor cells.
There is also hypothermia that,
according to the scientific literature,
combines quite well with standard of care.
There are many, many, many others.
I would say that, for cancer patients,
money is one thing, but not to lose time,
because often you are pressed on time.
I would go into the scientific literature
and try to find a little bit of information
about whatever other complementary therapy
you might be considering,
to see if it actually makes sense to treat cancer,
if the biological mechanism makes sense,
and if there are some published results
that might indicate that it might be helpful.
And lastly, this is my last slide.
I still have three minutes.
So I would like to address the controversy,
the skepticism, and the personal freedom
that I think patients should have.
The question we are asking is whether metabolic therapy
should be an adjuvant therapy,
something you do on the side,
or whether it should be the standard therapy for cancer.
Right now, for better or for worse,
each patient has the ultimate decision power.
This means that the burden of responsibility
is shifted from the oncologist back to the patient.
And I know this is an uncomfortable position to be in,
because you are facing life-threatening diagnosis,
and that's perhaps not the best time
to try to learn about cancer biology and cancer metabolism,
and understand how these things work.
So the protocols for metabolic therapy are being developed,
they are being tested in clinical research,
but right now, each case still needs to be individualized.
And I don't know if you remember the case of Brittany Maynard.
Brittany, this happened eight years ago.
Brittany was a young woman
that was diagnosed with glioblastoma, with brain cancer,
and she underwent surgery,
and then, as would be expected, the tumor came back,
and she decided to take her own life,
to commit medically-assisted suicide.
So I think she did the first level.
She understood very well what to expect
from standard of care, which, in case of brain cancer,
advanced brain cancer,
is basically virtually no benefit for survival.
And I think she saw no other option, no other alternative.
And if we compare this with Pablo Kelly,
Pablo Kelly, you have seen him
in yesterday's Cancer Revolution documentary,
and so he's still alive and well.
So it's a similar case.
Eight years ago, also, he was diagnosed with brain cancer.
He underwent surgery
and decided to not do chemotherapy and radiation
and just use ketogenic metabolic therapy
to manage his cancer.
So he just stayed in the second level.
He didn't even go to the third level
where we have more options.
And we are trying to publish these things,
so this is published by Dr. Seifried's team.
I think the more case reports we have
in the scientific literature,
they are useful for cancer patients to go in
and to learn about,
and if we have hundreds of patients,
then they will be difficult to ignore.
So I want to say that I understand the skepticism
and the frustration from oncologists
because there's a tendency to put everything
that is alternative into the same basket,
but metabolic therapy is not an alternative therapy.
It's based on a large body of scientific evidence.
And if treating cancer according to evolutionary biology
is considered alternative,
then I think we have a big, big problem in the cancer field.
So our hope and our effort is that very soon
metabolic therapy will be a part
of the standard oncology toolbox.
And I think one day it will be the first approach.
It's the first thing that you will try
when you are diagnosed with cancer.
And then if it doesn't work,
then of course there are many, many other options
that might be attempted.
And that's it.
I thank you very much for your attention.
Thank you.